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ABSTRACT
BACKGROUND: Proton pump inhibitors (PPIs) cost the French health care sys-
tem >€1 billion in 2005, and ~50% of PPI prescriptions were for the treatment of
gastroesophageal reflux disease (GERD).
OBJECTIVES: This study aimed to describe the current use of PPIs for GERD,
to estimate the total annual costs of treatment, and to evaluate the economic impact
of the various possible substitutions among PPIs available for this indication in
France.
METHODS: Data from a sample of patients aged ::0-20 years who visited their gen-
eral practitioner (GP) at least once in 2005 for uncomplicated, symptomatic GERD
were retrieved from the Thales database (a group of 1200 representative GPs con-
nected to a computerized network). Costs of the prescriptions presented for reim-
bursement and costs of those reimbursed by the French health care insurance system
were analyzed. We then evaluated the economic consequences of replacing full-dose
generic omeprazole (after substitution from brand-name omeprazole by the pharmacists)
with other compounds that are indicated for mild symptoms at half dose (ie, lansopra-
zole 15 mg, pantoprazole 20 mg, rabeprazole 10 mg, and esomeprazole 20 mg). The
results were adjusted to account for the proportions of patients who had full health care
coverage and the treatment duration as reported in the database. Results are presented
from the perspective of the French health care insurance system.
RESULTS: In 2005, a total of 122,571 patients (mean age, 55.7 years; 45.5% men;
13.8% with a history of at least 1 gastrointestinal disorder) met the inclusion criteria.
Extrapolated to the French population, this sample corresponded to ~5.7 million peo-
ple (ie, 13% of the adult population who visited a GP during the year). PPIs were
prescribed as first-line treatment for GERD in 84.1 % of the consultations (14.3% in
association with other antiulcer drugs). Omeprazole, as a proprietary or generic drug,
was prescribed most often (78.9%) and at full dose (20 mg), while other compounds
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(lansoprazole, pantoprazole, rabeprazole, and esomeprazole) were prescribed at half
dose in 64.3% of cases. The extrapolated annual cost of PPIs reimbursed for this in-
dication was €465 .02 million at a mean reimbursement level of72 .7%. Brand-name
omeprazole still accounted for ~ 11 % of the total cost reimbursed. Complete replace-
ment of brand-name omeprazole with its generic counterpart would have reduced
costs by €18.35 million (a decrease of 4.3% in the total reimbursed expenditure). The
switch from generic full-dose omeprazole to a half dose of other PPIs would have al-
lowed further savings ranging from €2.59 million (with lansoprazole) to €13.19 million
(with pantoprazole).
CONCLUSION: In accordance with recent recommendations for the treatment of
uncomplicated GERD and based on the 2006 PPI pricing, switching from branded
full-dose omeprazole to generic omeprazole or to the use of half doses of other PPIs
may allow cost savings in France. (Curr Ther Res Clin Exp. 2009;70:282-298) © 2009
Excerpta Medica Inc.
KEY WORDS: gastroesophageal reflux disease, proton pump inhibitors, pharma-
coeconomics, cost savings.
INTRODUCTION
Gastroesophageal reflux disease (GERD) is one of the most common conditions ob-
served in general medical practice and gastroenterology. 1 The condition may manifest
itself as peptic esophagitis and lead to complications such as esophageal ulcer, esopha-
geal stenosis, gastrointestinal bleeding, or metaplasia of the lower esophagus. Alarm
signs include weight loss, dysphagia, gastrointestinal bleeding, and anemia. GERD in
adult patients represents a real public health problem and is a major source of expen-
diture for the French health care insurance system. The prevalence of GERD is 10%
to 30% in the adult population of Western Europe, and 2 recent investigations in
French patients and general practitioners (GPs) suggested that it could be increasing.1,2
The frequency of the main symptom of GERD, heartburn, in the Western population
is 5% to 45% (ie, 5%-10% for a daily episode; 30%--45% for at least 1 episode
each month).
GERD is often a chronic disease, and two thirds of patients continue to complain
of symptoms after 5 to 10 years. In the general population, mild symptoms occurring
at least twice weekly, or moderate to severe symptoms occurring at least once weekly,
are often considered disturbing to patients. One quarter of adults experience nocturnal
heartburn, and, depending on the studies, 23% to 81 % of patients with GERD say
that their sleep is disturbed by GERD, with a consequent alteration in their quali-
ty of life as evaluated using general scales (eg, the 12-item Short Form Health Sur-
vey) or specific scales (eg, the Quality of Life Questionnaire in Gastroesophageal
Reflux). 2-4
In accordance with the conventional classification of GERD-related conditions,
proton pump inhibitors (PPIs) are approved for use in esophagitis at full dose and in
GERD at half dose. s A review article reported that the various PPIs display similar
dose-response relationships in terms of similar potencies and efficacies when given at
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the same milligram doses.s Although optimal dosages of omeprazole,* lansoprazole,t pan-
toprazole,+ and esomeprazole,§ are ~30 to 40 mg/d for the acute treatment of moderate to
severe GERD, lower daily dosages of lansoprazole, pantoprazole, and esomeprazole of
~ 15 to 20 mg/d may be sufficient for uncomplicated GERD and in maintenance therapy,
according to this review. More than half of prescriptions for uncomplicated GERD are ad-
ministered at full dose, even though lansoprazole, pantoprazole, rabeprazole,11 and esomepra-
zole have been approved for use in the treatment of uncomplicated GERD at half dose.
Treatment courses range from 2 weeks for pantoprazole to up to 4 to 6 weeks for omeprazole
or lansoprazole.S- ll Only omeprazole has also been approved for use in GERD at full dose
"in the event of insufficient response at the dose of 10 mg of omeprazole daily."9
An expert meeting held in January 1999 in France defined the modalities that
should be used to treat GERD in adults. 12 In patients aged < 50 years, the risk of se-
vere esophagitis or neoplastic lesions is low; therefore, patients with typical symptoms
(heartburn or acid regurgitation) and without any alarm signs can be diagnosed with
GERD in the absence of endoscopy. 12,13 In these patients, treatment is indicated with
antacids or histamine (H2) receptor inhibitors at low doses only when symptoms are
infrequent. However, symptoms of GERD are often better controlled by PPIs than by
antacids.s,6 If symptoms occur once weekly or several times weekly, continuous treat-
ment is indicated with a half-dose PPI for 4 weeks.S,12,13
The first 2 PPIs to be approved in France for use in GERD were omeprazole 10 mg
and lansoprazole 15 mg in 1996; these were followed by pantoprazole 20 mg in 1999
and esomeprazole 20 mg in 2000. 12 ,13 Omeprazole 20 mg and rabeprazole 10 mg
were given Market Authorization extensions in 2001 and 2002, respectively.
Generic omeprazole products have been available on the market since 2004.
Since being placed on the market in 1989 with approval for non-GERD conditions,
PPIs have represented a major expenditure and are the third most expensive class of
medicinal products for the French health care insurance system, just behind cholesterol-
lowering agents and drugs for arterial hypertension and cardiac insufficiency.l,12,13 In
2005, PPIs accounted for >€1 billion, or 5.7%, of the total expenditure on community-
dispensed drugs. 13 In a Dutch study, the cost of omeprazole (90% of the total market
share of PPIs in the Netherlands) for all indications increased from €68 million to
€230 million between 1993 and 2000. 14 The increase in PPI cost is partly linked to
the progressive extension of their reimbursable indications and, in particular, the in-
clusion of GERD, which now represents about half of PPI prescriptions in France
(2006 Thales database; http://www.thalesgroup.com).12.13 Between 2002 and 2005,
the number ofPPIs sold increased by a mean of 10% per year, from 36 million boxes
in 2002 to 48 million in 2005. Furthermore, together with the Spanish, the French
are the biggest consumers of PPIs in Europe.
*Trademark: Mopral® (AstraZeneca, Rueil-Malmaison, France).
t Trademarks: Lanzor® (sanofi-aventis, Paris, France); Ogast® (Takeda, Puteaux, France).
t Trademarks: Inipomp® (sanofi-aventis, Paris, France); Eupantol® (Altana Pharma, Le Mee-sur-Seine, France).
§ Trademark: Inexium® (AstraZeneca, Rueil-Malmaison, France).
II Trademark: Pariet® (Janssen-Cilag, Issy-les-Moulineaux, France).
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The medical profession is increasingly being encouraged to comply more closely
with clinical practice recommendations on the appropriate use of medicinal products,
and it was within this context that we conducted a study on the management of
GERD in general medical practice in France, using 2005 data from the Thales data-
base. The aims of this study were to describe the current use of PPls for symptomatic
GERD in general practice and to estimate the total annual costs to the French health
care insurance system of the management of symptomatic GERD with the various
PPI products marketed in France. Finally, we performed an economic evaluation of the
various possible substitutions among the PPls available for this indication, starting
with brand-name omeprazole.
METHODS
DATA SOURCE
Data used for this study were extracted from the Thales database, which consists of
the medical records of patients collected by 1200 GPs connected to a computerized
French network. These GPs are representative, in terms of age, sex, and geographic
distribution, of all G Ps in metropolitan France, allowing extrapolation of results to
the 56,000 GPs in France. 1s The system used to identify the physicians and consulta-
tions made it possible to establish a linkage between successive visits by a patient to a
particular GP in the network. This database thus provided the medical histories of a
cohort of > 1.2 million patients, including all prescriptions and associated diagnoses.
PATIENT SELECTION
Because all data accessed were delinked from patients' identifiers, ethics committee
approval was not required in the present study; a waiver of consent was obtained from
the ethics committee before the start of data collection. Patients aged ::0-20 years who
had visited a GP from the network at least once in 2005 and had received a diagnosis
of symptomatic, uncomplicated GERD (gastroesophageal reflux or simple GERD) or
corresponding symptoms (esophagogastric reflux, esophageal burning, esophageal
pain, heartburn, postural heartburn, or regurgitation)1-3,S were selected from the
Thales database and included in the analysis. Selected patients had no serious signs
such as weight loss, dysphagia, gastrointestinal bleeding, or anemia. Patients with
esophagitis with or without signs of bleeding, as identified by upper gastrointestinal
endoscopy, or with esophageal or gastric cancer were not included in the economic
analysis. The following data were collected for all patients who met the inclusion
criteria: sex, age, number of consultations with a diagnosis (or symptoms) of GERD
(simple GERD), prescription (or not) for a PPI during these visits, and comorbid condi-
tions. For the subgroup of patients who were monitored by physicians for at least
1 year, the number of PPI prescriptions during the previous year for the GERD indica-
tion was also recorded. We did not analyze low-dose aspirin or other NSAID intake.
COST ANALYSES
Cost analyses were limited to pharmaceutical costs related to the prescription of
PPls for uncomplicated GERD in general medical practice. Two types of costs were
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included: the costs of the prescriptions presented for reimbursement and the costs
currently reimbursed by the French health care insurance system. Our estimates were
initially based on prescriptions and not on the pharmacist's billing form. However,
pharmacists generally substitute some of these prescriptions, and we did not have
direct access to this information. On the basis of the various data available comparing
prescriptions versus effective sales at the pharmacy (http://www.gie-gers.fr/actualites/
cC-Een.php3 and http://www.imshealth.com/portal/site/imshealth). we assumed that
for ~50% of prescriptions for brand-name omeprazole, the pharmacists substituted
generic omeprazole. Consequently, we integrated this substitution into our cost cal-
culations. We hypothesized that when pharmacists did switch, treatment durations
remained unchanged.
In our estimate of the pharmaceutical cost of GERD for the year 2005, we used
unit prices that were current on December 31, 2005. However, in our study about
possible substitutions between products, we used the current prices (as of Decem-
ber 31, 2006) to integrate the decline in esomeprazole price that was applicable from
December 20, 2006, onward (Table 1). We evaluated the economic consequences of
replacing full-dose generic omeprazole (after substitution by community pharmacists,
as estimated previously) with other compounds at half dose. This evaluation was per-
formed directly on the basis of the number of prescriptions observed in 2005 in the
Thales panel, extrapolated to all French GPs. The principle of this calculation con-
sisted of successively replacing the total extrapolated cost of prescriptions of full-
dose generic omeprazole for GERD in 2005 with the corresponding mean cost of
prescriptions of other compounds at half dose. We then adjusted these results to
take into account the proportions of patients who had full coverage (100% reim-
bursement) by the French health care insurance system as well as the treatment
duration as reported in the database.
RESULTS
DEMOGRAPHIC DATA
The study included 122,571 patients listed in the Thales database who met the
inclusion criteria. After extrapolation to the entire French population, this number
corresponded to ~5.7 million patients, or 13% of the total population aged ;;,20 years
who had consulted 1 of the physicians from the panel at least once in 2005; the num-
ber was also consistent with the epidemiologic data available on the prevalence of
GERD.1-3 Overall, 54.5% were women and 45.5% were men, and the mean age of
the patients was 55.7 years. The prevalence of symptomatic GERD ranged from a low
of 5.8% at ages 20 to 29 years to a high of 24.1 % at ages 50 to 59 years. Among these
patients, 11.8% had full (ie, 100%) health care coverage by the French health care insur-
ance system for chronic illness ("affections de longue duree"), pooling all causes.
The group of patients treated for GERD with PPIs represented 271,214 consulta-
tions, or 84.1 % of the total number of consultations analyzed. In this group, the
frequencies of risk factors were as follows: arterial hypertension (33.7%), non-insulin-
dependent diabetes mellitus (8.6%), coronary heart disease (7.9%), active smoking
(7.8%), HDL-C <0.4 giL (2.5%), and a family history of cardiovascular disease (2%).
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Table I. Proton pump inhibitors available in France: dose, brand names, and unit prices
as of December 31, 2006.
Half Dose or Prices, €
Drug Dose, mg Full Dose Brand Names (28-Pill Boxes)
Omeprazole 10 Half dose Mopral®* 22.60
Zoltum®* 22.60
Generic 15.46
20 Full dose Mopral® 41.85
Zoltum® 41.85
Generic 24.47
Lansoprazole 15 Half dose Lanzor®t 22.82 (30-pill box)
Ogast®t 22.82 (30-pill box)
30 Full dose Lanzor® 39.36
Ogast® 39.36
Pantoprazole 20 Half dose Eupantol®§ 21.56
Inipomp®t 21.56
40 Full dose Eupantol® 40.28
Inipomp® 40.28
Rabeprazole 10 Half dose Pariet®11 20.50
20 Full dose 37.76
Esomeprazole 20 Half dose Inexium®* 28.71
40 Full dose 33.76
*AstraZeneca, Rueil-Malmaison, France.
t sanofi-aventis, Paris, France.
t Takeda, Puteaux, France.
§ Altana Pharma, Le Mee-sur-Seine, France.
II Janssen-Cilag, Issy-Ies-Moulineaux, France.
A history of at least 1 gastrointestinal disorder was observed in 13.8% of patients
treated with PPIs and included irritable bowel syndrome (7.1 %), gastritis (4.7%),
esophagitis 0.4%), gastric ulcer (1.0%), duodenal ulcer (0.5%), and gastroduodenal
ulcer (0.2%). Some patients had more than one condition.
CONSULTATIONS AND TREATMENTS PRESCRIBED
In 2005, the 122,571 patients identified visited their GP a mean of 7.5 times
(pooling all reasons). The annual number of consultations for GERD varied from 1 to
> 10 per patient, and >84% of patients (ie, 103,379) consulted their GP between
1 and 4 times for symptoms related to GERD (Table II). Of the 322,633 consultations
for GERD recorded in 2005, a total of 84.1 % resulted in a PPI prescription, of which
69.8% were for a PPI alone and 14.3% were for a PPI in association with other anti-
ulcer drugs (Table III). For the rest of the 322,633 consultations for GERD, only
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Table II. Distribution of patients according to the number of general-practitioner (GP)
consultations for gastroesophageal reflux disease (GERD) in 2005 in France.*
No. of GP No. of
Consultations for GERD Patients %
1 55,468 45.3
2 24,231 19.8
3-4 23,680 19.2
5-6 10,481 8.6
7-8 4016 3.3
9-10 2119 1.7
>10 2576 2.1
Total 122,571 100
*Includes patients with at least 1 consultation in the Thales database (http://www.thalesgroup.com;
Thales, Boulogne, France).
3.5% resulted in a prescription for antiulcer drugs other than a PPI, and in 12.4% of
cases, no drug was prescribed for GERD.
As shown in Figure 1, omeprazole (brand name or generic) was the most frequently
prescribed PPI, mainly at full doses (78.9% [23.2/29.4} of cases). Omeprazole repre-
sented 29.4% of all prescribed PPIs, followed by pantoprazole (22.3%), lansoprazole
(20.8%), esomeprazole (14.0%), and rabeprazole (13.5%). Unlike omeprazole, the
other PPIs (pantoprazole, lansoprazole, esomeprazole, and rabeprazole) were pre-
scribed at half dose in 64.3% of cases (45.4170.6) (Figure 1). Patients took 1 tablet
daily on average regardless of the dosing regimen (half or full dose). The mean treat-
ment duration ranged from 41.0 days (with pantoprazole) to 50.7 days (with brand-
name omeprazole) when given at half dose and from 39.5 days (pantoprazole) to
55.9 days (brand-name omeprazole) when given at full dose (Table IV). Among patients
to whom omeprazole was prescribed, up to 31.3% had full health care coverage, com-
pared with 7.8% to 17.6% of patients taking 1 of the other PPIs analyzed (Table IV).
Among the 93,131 patients already being monitored by their GP for GERD during
the previous year, 43.8% had already received at least 1 prescription for PPIs during
that year (mean, 1.4).
Switching between products was relatively rare. Indeed, PPI prescriptions were
renewed with the same drug at the same dose in 58.6% to 81.5% of cases depending
on the drug prescribed, with the exception of generic omeprazole, which was renewed
in only 29.2% of cases when taken at half dose and in 57.2% when taken at full dose
(Table IV). When there was a change in PPI, it typically involved a change to another
dose of the same drug, usually from the half dose to the full dose for omeprazole
(brand name or generic), reflecting an intensification in treatment, and from the full
dose to the half dose for the other compounds, reflecting a switch to maintenance
therapy.
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Table III. Number of general-practitioner consultations for gastroesophageal reflux dis-
ease (GERD) and amount of proton pump inhibitors (PPls) prescribed in 2005
in France.*
Result of the Consultation
Consultations with a diagnosis of GERD
Consultations with a PPI prescription alone
Consultations with a prescription for PPls plus other medications
PPI + antacids
PPI + modulators of intestinal motility
PPI + antiflatulents
PPI + other
Consultations with a prescription of medications other than PPls
Antacids
H2-receptor antagonists
Modulators of intestinal motility
Antacids + modulators of intestinal motility
Antiflatulents
Other
No prescription
No. of Consultations (%)
322,633 (100)
225,120 (69.8)
46,094 (14.3)
15,867 (4.9)
15,354 (4.8)
7877 (2.4)
6996 (2.2)
11,312 (3.5)
4974 (1.5)
1861 (0.6)
1588 (0.5)
911 (0.3)
693 (0.2)
1285 (0.4)
40,107 (12.4)
H2 = histamine.
*Thales database, 2005 (http://www.thalesgroup.com; Thales, Boulogne, France).
COST ANALYSIS
By extrapolating the results of previous analyses (Thales database, data not shown)
concerning prescriptions of PPIs for uncomplicated GERD in 2005 and integrating
the substitutions by pharmacists, we estimated the total cost of PPI prescribing for
GERD at €639.84 million. Of this total, €465.02 million was effectively reimbursed
by the French health care insurance system, for a mean rate of reimbursement of 72.7 %.
We observed a fairly homogeneous distribution of costs for the various compounds,
ranging from 13% to 19% of the total cost for each one, as well as a fairly even half-
dose to full-dose distribution for each compound, with the exception of omeprazole.
For omeprazole (brand name or generic), the full-dose prescription costs were ~4 to
10 times higher than the half-dose costs, especially for the generic product (2% at half
dose vs 19% at full dose). In general, we found that the full-dose prescriptions were
always more likely than the half-dose prescriptions to be reimbursed 100% (Table IV
and Figure 2). Furthermore, the prescriptions of brand-name omeprazole were 100%
reimbursed more frequently than the other compounds (Table IV and Figure 2). The
corresponding patients (ie, those for whom omeprazole was prescribed) were older (mean
age, 65 years, vs 55 years for the other compounds). The mean costs per prescription
(full costs and reimbursements) according to drug product and dose are presented in
Figure 2. The differences observed might be explained by several factors, including
unit price of the products (Table 1), daily dose, and mean reimbursement rates.
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Figure 1. Distribution in percentages of proton pump inhibitors prescribed in 2005 per
product and dose for uncomplicated gastroesophageal reflux disease treated in
general practice in France.
ECONOMIC IMPACT OF PRODUCT SUBSTITUTION
In 2005 and on the basis of the data analyzed in this study, there was still opportu-
nity for substitution between brand-name omeprazole and generic omeprazole or the
other available compounds because brand-name omeprazole still accounted for ~ 11%
of the total cost of drug products in the GERD indication (after substitutions by the
pharmacists). Thus, in terms of the consumption observed in metropolitan France in
2005, completely replacing brand-name omeprazole with its generic counterpart at
the same dosing regimen and for the same duration, based on the prices available on
December 31, 2006, would have represented a savings of €18.35 million for the
French health care insurance system (€21.2 million of the total cost). This savings
represents a decrease of 4.3% in the total amount of reimbursed expenditures.
Figure 3 describes the potential annual cost savings for the French health care in-
surance system from using the other PPIs in place of full-dose generic omeprazole,
both with and without adjustment for the percentage of patients with full health care
insurance coverage as mentioned in Table IV (prescriptions by GPs in 2005; retail
prices as of December 31, 2006, in euros). As shown in Figure 3, an additional cost
was associated with substituting full-dose omeprazole with half-dose esomeprazole
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Table IV. Proton pump inhibitors (PPls) prescribed by general practitioners for patients with gastroesophageal reflux disease in
2005 in France: dosing regimen, prescription renewal rate, prescription duration, and health care coverage.
Half-Dose PPI Full-Dose PPI
Renewal Prescription Full Health Care Renewal Prescription Full Health Care
Rate, Duration, Coverage, Rate, Duration, Coverage,
Medication % d % % d %
Omeprazole (brand name) 81.5 50.7 21.9 78.6 55.9 31.3
Omeprazole (generic) 29.2 41.8* 15.5 57.2 44.1* 20.0
Lansoprazole 65.3 44.3 8.1 65.5 47.2 12.2
Pantoprazole 58.6 41.0 7.8 59.7 39.5 11.2
Rabeprazole 62.8 45.9 7.8 65.6 45.3 12.3
Esomeprazole 59.7 44.9 11.0 63.3 45.4 17.6
*For generic omeprazole, this relates to dispensing after substitution by pharmacists.
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• Mean cost reimbursed per prescription
D Mean full cost per prescription
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Brand-Name Esomeprazole Lansoprazole Rabeprazole Pantoprazole Generic
Omeprazole Omeprazole
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Brand-Name Lansoprazole Esomeprazole Rabeprazole Pantoprazole Generic
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Full Dose
Figure 2. Mean reimbursed cost and full cost per proton pump inhibitor prescription given
at (A) half dose and (B) full dose for gastroesophageal reflux disease in general
practice in France after substitution by pharmacists (retail prices as of Decem-
ber 31, 2005, in euros).
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Figure 3. Potential annual cost savings for the French health care insurance system
associated with the substitution of full-dose generic omeprazole with other
proton pump inhibitors at half dose, without and with adjustment for the per-
centage of patients with full health care coverage (prescriptions by general
practitioners in 2005; retail prices as of December 31, 2006, in euros).
(+€2.72 million with adjustment and +€6.32 million without adjustment). In con-
trast, savings were achieved by substituting half-dose lansoprazole (-€7.43 and
-€2.59 million), half-dose pantoprazole (-€8.99 and -€13.19 million), and half-dose
rabeprazole (-€10.55 and -€8.81 million). These findings were directly related to the
differences in unit costs per prescription shown in Figure 2.
DISCUSSION
The description of this population allowed us to ensure that we had indeed targeted
patients with uncomplicated GERD. PPIs have become the first-line choice in France
for the treatment of symptomatic, uncomplicated GERD (ie, without alarm signs) in
adults, accounting for 84.1 % of patients at a given time during the year. For this indica-
tion, brand-name or generic omeprazole is mainly prescribed at full dose (20 mg),
whereas the other compounds (lansoprazole, pantoprazole, rabeprazole, and esomepra-
zole) are prescribed mainly at half dose. As first-line drug therapy, the half dose is
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recommended for all the products, but in clinical practice, the full dose is used more
often with omeprazole, in compliance with clinical trial findings. s- s
Complete dose-for-dose substitution of brand-name omeprazole with its generic
counterpart (therefore generally given at full dose) would have led to an estimated
savings of €18.35 million in 2006. Moreover, brand-name omeprazole could be sub-
stituted with PPIs given for GERD at half dose. 12 ,13 The switch to these PPIs would
represent an additional savings potential of a similar magnitude, especially when con-
verting to pantoprazole (additional savings of €8.99 million with adjustment and
€13.19 million without adjustment for health care coverage) or rabeprazole (addi-
tional savings of €10.55 million with adjustment and €8.81 million without adjust-
ment). These calculations were enhanced by considering the differences in the pre-
scription durations and the percentages of patients who had full health care coverage
by French health insurance. These adjustments made it possible to simulate the pre-
cise conditions of substitution if carried out by the community pharmacist, and the
adjustments considerably modified the results obtained. For example, the number of
patients reimbursed at 100% for brand-name omeprazole was substantially higher than
the number reimbursed at 100% for the other products. In addition, the mean prescrip-
tion duration for full-dose generic omeprazole was shorter than the corresponding dura-
tions for the other products at half dose, with the exception of pantoprazole.
Justification for the substitution of omeprazole was based on several studies that
suggested that half doses of lansoprazole, pantoprazole, rabeprazole, or esomeprazole
are clinically equivalent to full doses of omeprazole in terms of efficacy for relieving
symptoms in patients with uncomplicated GERD.s-7,16-19 Pantoprazole and esomep-
razole, for instance, have been found to have comparable efficacy at half doses in
2 prospective, randomized controlled trials enrolling patients with uncomplicated
GERD, with effective symptom relief in at least 65% of cases. 20 ,21 Furthermore, for
other indications such as prophylaxis of gastroduodenal lesions linked to NSAIDs in
at-risk patients, omeprazole 20 mg (full dose) and pantoprazole 20 mg (half dose) had
similar efficacy, with at least 65 % of patients reporting effective symptom relief ac-
cording to a self-based assessment. 22 For patients with GERD, the optimal efficacy of
omeprazole does not appear to be achieved at half dose because the 20-mg formulation
is indicated in the event of insufficient response, defined as <50% of effective symp-
tom relief, to the 10-mg formulation. 9 This dosing information was confirmed in
4 clinical trials comparing the 2 formulations, as referred to in the Transparency Com-
mission opinion, which stated that omeprazole appeared to be more effective at full
dose than at half dose. 23 Furthermore, it should be noted that in the United States,
omeprazole 10 mg is reserved for children weighing <20 kg, and 20 mg is the recom-
mended dose for the treatment of GERD in adults; a 40-mg dose is also available. 16
The Market Authorization states that the duration of GERD treatment with PPIs
varies from 2 to 6 weeks. In our study, treatment duration appeared to be shorter with
pantoprazole. Three studies have confirmed the efficacy of pantoprazole 20 mg in the
treatment of uncomplicated GERD after 2 weeks. 24- 26 In the first study, pantoprazole
was effective in relieving the symptoms of heartburn in 69% of the patients after
1 week (vs 34% with placebo; P < 0.001) and in 80% of the patients after 2 weeks
294
S. MOULY ET AL.
(vs 46% with placebo; P < 0.001).24 In the prospective, randomized controlled study
by Dettmer et al,25 the proportion of patients reporting complete relief of symptoms
after 2 weeks of treatment was significantly greater with pantoprazole (69% vs 48%
with ranitidine; P < 0.01), and there was further relief after 4 weeks (80% vs 65%;
P < 0.05). Finally, in the third prospective study using the same design, 80% of the
patients treated with pantoprazole reported complete relief of symptoms after 2 weeks
(vs 51 % with ranitidine; P < 0.001), and further relief was recorded after 4 weeks
(88% vs 58%; P < 0.001).26 In terms of costs, a Dutch meta-analysis comparing pan-
toprazole 20 mg and 40 mg with omeprazole 20 mg in the treatment of symptomatic
GERD and peptic ulcer showed that it would be possible to achieve an annual cost
savings of €40.8 million if at least 90% of omeprazole prescriptions were substituted
with pantoprazole; no recurrence of symptoms was found during pantoprazole treat-
ment at the recommended dosage of 20 mg/d. 14
The present study had several limitations. We did not compare our cost-savings
strategy with the additional savings potential of a recently published and well-accepted
on-demand treatment strategy for uncomplicated, symptomatic GERD, whereby
patients are treated with PPIs after they have complete resolution of heartburn symp-
toms following 4 weeks of open-label acute PPI treatment. 27- 29 Although this GERD
management strategy is increasingly common for long-term therapy, we are not aware
of any objective, well-designed clinical efficacy data on its use. 27 ,30 A recent prospec-
tive observational study conducted in 927 patients receiving GERD therapy, either
daily or on demand, has shown that only 36% of them were asymptomatic at the time
of the study and an additional 20.5% were also taking at least 1 over-the-counter
medication,3l Whether the present economic approach will be effective and meet
patients' needs in terms of symptom relief deserves further prospective randomized or
epidemiologic evaluations.32,33
In patients aged <;50 years, the risk of severe esophagitis or neoplastic lesions is low;
therefore, patients with typical symptoms (heartburn or acid regurgitation) and with-
out any alarm signs can be treated for GERD with antacids or H 2-receptor inhibitors
at low doses, especially if symptoms are infrequent. 12 The latter group of first-line
therapies was used in only 3.5% of the present population. Therefore, although the
potential cost savings of such a strategy may have been even greater than those of the
substitution strategy evaluated in the present study, those potential savings were not
evaluated. Alternatively, a cost-effectiveness approach might have been more clinically
relevant, but the present pharmacoeconomic approach was not designed to evaluate
the cost-effectiveness of the different substitution strategies proposed.6,7
Finally, whether the cost-saving strategy in this study will decrease the long-term
costs of treatment for uncomplicated, symptomatic GERD will require further eco-
nomic evaluations.34,35 Our study also highlighted the need for medical-economic
evaluations that include further data in addition to drug acquisition costs.
CONCLUSIONS
The economic approach presented here made it possible to describe the current pre-
scribing practices and estimate the costs of PPIs for uncomplicated, symptomatic
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GERD in general medical practice in France. In accordance with recent recommenda-
tions for the treatment of uncomplicated GERD and based on the 2006 PPI pricing,
switching from branded full-dose omeprazole to generic omeprazole or to the use of
half doses of other PPIs may achieve cost savings.
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